Epalrestat
Names | |
---|---|
Preferred IUPAC name
{(5Z)-5-[(2E)-2-Methyl-3-phenylprop-2-en-1-ylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl}acetic acid | |
Identifiers | |
3D model (
JSmol ) |
|
ChEBI | |
ChEMBL | |
ChemSpider | |
ECHA InfoCard
|
100.200.343 |
KEGG | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C15H13NO3S2 | |
Molar mass | 319.401 g/mol |
Density | 1.43 g/cm3 |
Melting point | 210 °C (410 °F; 483 K) |
Boiling point | 516.8 °C (962.2 °F; 789.9 K) |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Epalrestat is a carboxylic acid derivative
Evidence
It has been demonstrated in animal experiments that there is an improvement in sorbitol levels and Na+/K+ ATPase activity leading to improved nerve conduction velocity. Diabetic rats treated with epalrestat showed improvement in morphological abnormalities of nerves.[8] In a placebo controlled double blind trial of 196 patients, it was shown that Epalrestat in a dose of 150 mg/day improved the effects of diabetic neuropathy like upper limb spontaneous pain, motor nerve conduction velocity, thresholds of vibratory sensation and autonomic nerve function as compared to a placebo. These effects were significantly better in those with poorer control of diabetes.[9] A systematic review and metaanalysis showed that based on the results of 10 articles, it can be concluded that Epalrestat has some benefit in the control of diabetic cardiovascular autonomic neuropathy but only in the early or mild cases. It also doesn't influence glycaemic control.[10]
Brand names
- Aldonil (Zydus Medica), India
- Aldorin, Bangladesh
- Alrista (marketed and not manufactured by Macleods), India
- Epalrica-M (Ordain Global), India
- Eparel 50 (Microlabs Ltd), India
- Epimeth (Zaiva Lifesciences), India
- Eplistat 150 SR (Schem), India
- Letostat-SR (Amor Pharmaceuticals), India
- Listap-50 (Vivid Biotek), India
- Tanglin (Yangtze River Pharmaceutical Group), China
References
- PMID 6423811.
- S2CID 207233270.
- PMID 8312678.
- S2CID 207233270.
- PMID 16801576. Retrieved 16 July 2016.
- PMID 6423811.
- PMID 8807467.
- ^ Hotta, N; Sugimura, K; Kakuta, H; Fukasawa, H; Kimura, M; Koh, N (1988). Effects of a fructose rich diet and an aldose reductase inhibitor on the development of diabetic neuropathy in streptozotocin-treated rats. Amsterdam: Elsevier Science Publishers BV. p. 511.
- PMID 7579007.
- PMID 24533052.
External links